secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001213900-26-037474
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.01
LLM model:  deepseek-v4-flash:cloud

Oramed Pharmaceuticals completes sale of subsidiary Oratech to Lifeward and purchases $9M convertible notes
--------------------------------------------------------------------------------

- Lifeward acquired Oramed's wholly-owned subsidiary Oratech for 1,250,363 ordinary shares, 1,006,113 pre-funded warrants, and share purchase warrants.
- Oramed purchased $9,000,000 aggregate principal of Lifeward senior secured convertible notes with initial conversion price of $5.40 per share.
- Oramed also received purchase agreement warrants to buy up to 1,666,666 Lifeward ordinary shares at $5.40 per share.
- Oramed is entitled to ongoing revenue sharing payments equal to 4% of net revenue from Lifeward's ReWalk exoskeleton products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/0001213900-26-037474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/ea0284244-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-037474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer